NCT07020221 2026-04-03
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
Verastem, Inc.
Bristol-Myers Squibb
Eli Lilly and Company
Eli Lilly and Company
Gilead Sciences
Eli Lilly and Company
Eli Lilly and Company